Cargando…
Interventional Treatment Strategies in Intrahepatic Cholangiocarcinoma and Perspectives for Combined Hepatocellular-Cholangiocarcinoma
SIMPLE SUMMARY: Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is a rare form of liver cancer with features of both hepatocellular and biliary tract cancer. Locoregional tumor therapies are an integral part of the treatment strategies of hepatocellular carcinomas (HCC) and intrahepatic cholan...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10177209/ https://www.ncbi.nlm.nih.gov/pubmed/37174120 http://dx.doi.org/10.3390/cancers15092655 |
_version_ | 1785040584139866112 |
---|---|
author | Auer, Timo Alexander Collettini, Federico Segger, Laura Pelzer, Uwe Mohr, Raphael Krenzien, Felix Gebauer, Bernhard Geisel, Dominik Hosse, Clarissa Schöning, Wenzel Fehrenbach, Uli |
author_facet | Auer, Timo Alexander Collettini, Federico Segger, Laura Pelzer, Uwe Mohr, Raphael Krenzien, Felix Gebauer, Bernhard Geisel, Dominik Hosse, Clarissa Schöning, Wenzel Fehrenbach, Uli |
author_sort | Auer, Timo Alexander |
collection | PubMed |
description | SIMPLE SUMMARY: Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is a rare form of liver cancer with features of both hepatocellular and biliary tract cancer. Locoregional tumor therapies are an integral part of the treatment strategies of hepatocellular carcinomas (HCC) and intrahepatic cholangiocarcinoma (iCCA). Due to the rarity of cHCC-CCA, no interventional therapies have been established. This review provides an overview of current radiologic interventions for CCA (excluding options for eCCA), to review and appraise the existing literature on the topic, and to provide an outlook on whether such interventions may have a role as treatment for cHCC-CCA in the future. ABSTRACT: cHCC-CCA is an uncommon type of liver cancer that exhibits clinical and pathological characteristics of both hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA), which are the two main forms of primary liver cancer. The similarity to HCC and CCA makes therapeutical strategies challenging. The poor prognosis of CCA in general, as well as for cHCC-CCA, is mainly attributable to the fact that diagnosis is often at an advanced stage of disease. During the last decade, locoregional therapies usually performed by interventional radiologists and its established role in HCC treatment have gained an increasing role in CCA treatment as well. These comprise a wide range of options from tumor ablation procedures such as radiofrequency ablation (RFA), microwave ablation (MWA), computed tomography high-dose rate brachytherapy (CT-HDRBT), and cryoablation to transarterial chemoembolization (TACE), including the option of intra-arterial administration of radioactive spheres (transarterial radioembolization—TARE), and much attention has focused on the potential of individual concepts in recent years. The purpose of this review is to provide an overview of current radiologic interventions for CCA (excluding options for eCCA), to review and appraise the existing literature on the topic, and to provide an outlook on whether such interventions may have a role as treatment for cHCC-CCA in the future. |
format | Online Article Text |
id | pubmed-10177209 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-101772092023-05-13 Interventional Treatment Strategies in Intrahepatic Cholangiocarcinoma and Perspectives for Combined Hepatocellular-Cholangiocarcinoma Auer, Timo Alexander Collettini, Federico Segger, Laura Pelzer, Uwe Mohr, Raphael Krenzien, Felix Gebauer, Bernhard Geisel, Dominik Hosse, Clarissa Schöning, Wenzel Fehrenbach, Uli Cancers (Basel) Review SIMPLE SUMMARY: Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is a rare form of liver cancer with features of both hepatocellular and biliary tract cancer. Locoregional tumor therapies are an integral part of the treatment strategies of hepatocellular carcinomas (HCC) and intrahepatic cholangiocarcinoma (iCCA). Due to the rarity of cHCC-CCA, no interventional therapies have been established. This review provides an overview of current radiologic interventions for CCA (excluding options for eCCA), to review and appraise the existing literature on the topic, and to provide an outlook on whether such interventions may have a role as treatment for cHCC-CCA in the future. ABSTRACT: cHCC-CCA is an uncommon type of liver cancer that exhibits clinical and pathological characteristics of both hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA), which are the two main forms of primary liver cancer. The similarity to HCC and CCA makes therapeutical strategies challenging. The poor prognosis of CCA in general, as well as for cHCC-CCA, is mainly attributable to the fact that diagnosis is often at an advanced stage of disease. During the last decade, locoregional therapies usually performed by interventional radiologists and its established role in HCC treatment have gained an increasing role in CCA treatment as well. These comprise a wide range of options from tumor ablation procedures such as radiofrequency ablation (RFA), microwave ablation (MWA), computed tomography high-dose rate brachytherapy (CT-HDRBT), and cryoablation to transarterial chemoembolization (TACE), including the option of intra-arterial administration of radioactive spheres (transarterial radioembolization—TARE), and much attention has focused on the potential of individual concepts in recent years. The purpose of this review is to provide an overview of current radiologic interventions for CCA (excluding options for eCCA), to review and appraise the existing literature on the topic, and to provide an outlook on whether such interventions may have a role as treatment for cHCC-CCA in the future. MDPI 2023-05-08 /pmc/articles/PMC10177209/ /pubmed/37174120 http://dx.doi.org/10.3390/cancers15092655 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Auer, Timo Alexander Collettini, Federico Segger, Laura Pelzer, Uwe Mohr, Raphael Krenzien, Felix Gebauer, Bernhard Geisel, Dominik Hosse, Clarissa Schöning, Wenzel Fehrenbach, Uli Interventional Treatment Strategies in Intrahepatic Cholangiocarcinoma and Perspectives for Combined Hepatocellular-Cholangiocarcinoma |
title | Interventional Treatment Strategies in Intrahepatic Cholangiocarcinoma and Perspectives for Combined Hepatocellular-Cholangiocarcinoma |
title_full | Interventional Treatment Strategies in Intrahepatic Cholangiocarcinoma and Perspectives for Combined Hepatocellular-Cholangiocarcinoma |
title_fullStr | Interventional Treatment Strategies in Intrahepatic Cholangiocarcinoma and Perspectives for Combined Hepatocellular-Cholangiocarcinoma |
title_full_unstemmed | Interventional Treatment Strategies in Intrahepatic Cholangiocarcinoma and Perspectives for Combined Hepatocellular-Cholangiocarcinoma |
title_short | Interventional Treatment Strategies in Intrahepatic Cholangiocarcinoma and Perspectives for Combined Hepatocellular-Cholangiocarcinoma |
title_sort | interventional treatment strategies in intrahepatic cholangiocarcinoma and perspectives for combined hepatocellular-cholangiocarcinoma |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10177209/ https://www.ncbi.nlm.nih.gov/pubmed/37174120 http://dx.doi.org/10.3390/cancers15092655 |
work_keys_str_mv | AT auertimoalexander interventionaltreatmentstrategiesinintrahepaticcholangiocarcinomaandperspectivesforcombinedhepatocellularcholangiocarcinoma AT collettinifederico interventionaltreatmentstrategiesinintrahepaticcholangiocarcinomaandperspectivesforcombinedhepatocellularcholangiocarcinoma AT seggerlaura interventionaltreatmentstrategiesinintrahepaticcholangiocarcinomaandperspectivesforcombinedhepatocellularcholangiocarcinoma AT pelzeruwe interventionaltreatmentstrategiesinintrahepaticcholangiocarcinomaandperspectivesforcombinedhepatocellularcholangiocarcinoma AT mohrraphael interventionaltreatmentstrategiesinintrahepaticcholangiocarcinomaandperspectivesforcombinedhepatocellularcholangiocarcinoma AT krenzienfelix interventionaltreatmentstrategiesinintrahepaticcholangiocarcinomaandperspectivesforcombinedhepatocellularcholangiocarcinoma AT gebauerbernhard interventionaltreatmentstrategiesinintrahepaticcholangiocarcinomaandperspectivesforcombinedhepatocellularcholangiocarcinoma AT geiseldominik interventionaltreatmentstrategiesinintrahepaticcholangiocarcinomaandperspectivesforcombinedhepatocellularcholangiocarcinoma AT hosseclarissa interventionaltreatmentstrategiesinintrahepaticcholangiocarcinomaandperspectivesforcombinedhepatocellularcholangiocarcinoma AT schoningwenzel interventionaltreatmentstrategiesinintrahepaticcholangiocarcinomaandperspectivesforcombinedhepatocellularcholangiocarcinoma AT fehrenbachuli interventionaltreatmentstrategiesinintrahepaticcholangiocarcinomaandperspectivesforcombinedhepatocellularcholangiocarcinoma |